Literature DB >> 12636389

Amino-zinc-enolate carbometalation reactions: application to ring closure of terminally substituted olefin for the asymmetric synthesis of cis- and trans-3-prolinoleucine.

Philippe Karoyan1, Jean Quancard, Jacqueline Vaissermann, Gérard Chassaing.   

Abstract

The amino-zinc-enolate cyclization reaction is a straightforward route for the synthesis of 3-substituted prolines. As classical intramolecular carbometalation reactions, the applicability of the addition of zinc to a double bond was limited to a substrate in which the terminal alkene carbon was unsubstituted. Being interested in the synthesis of cis- and trans-3-prolinoleucine derivatives for our structure-activity relation (SAR) studies, we focused our effort on the preparation of these compounds by amino-zinc-enolate cyclization of terminally substituted double bonds. Herein we report that the attachment of an activating group such as cyclopropyl to the terminal olefin carbon allows the amino-zinc-enolate cyclization of a terminally substituted alkene. The reaction is stereospecific, leading to a trans-3-substituted proline derivative, whereas a cis stereochemistry was observed with the amino-zinc-enolate cyclization of terminally nonsubstituted olefins. Absolute configurations obtained for the 3-prolinoleucine were established by X-ray analysis, NMR, and optical activity comparison of the cis and trans derivatives obtained by an unambiguous pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636389     DOI: 10.1021/jo026535n

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  1 in total

Review 1.  3-Substituted prolines: from synthesis to structural applications, from peptides to foldamers.

Authors:  Céline Mothes; Cécile Caumes; Alexandre Guez; Héloïse Boullet; Thomas Gendrineau; Sylvain Darses; Nicolas Delsuc; Roba Moumné; Benoit Oswald; Olivier Lequin; Philippe Karoyan
Journal:  Molecules       Date:  2013-02-19       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.